Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Blood|July 24, 2024
KDM6A regulates immune response genes in multiple myelomaDaphné Dupéré-Richer, Alberto Riva, Benjamin G Barwick, et al.
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.
Blood|April 10, 2024
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenomeAmin Sobh, Elena Encinas, Alisha Patel, et al.
Cancer Research Communications|November 13, 2023
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 InhibitorsDennis Juarez, Roberta Buono, Shannon M Matulis, et al.
American Journal of Hematology|December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myelomaJonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
Blood Cancer Discovery|November 7, 2023
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaPaola Neri, Benjamin G Barwick, David Jung, et al.
The Journal of Biological Chemistry|May 5, 2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancersLiang Zhao, Jun Fan, Siyuan Xia, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Blood|December 18, 2024
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesisRemya Nair, An H Vu, Abigail K Freer, et al.
Blood Cancer Discovery|October 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3Mariateresa Fulciniti, Yao Yao, Tommaso Perini, et al.
Pageof 13